NCT01149993

Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Georgetown University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Patients undergoing living donor renal transplant will be asked to participate to determine whether pre-operative dosing of immunosuppressive medication, and the donor organ receiving an additional dose of antibody induction therapy helps to alleviate potential damage to the transplanted organ post-transplant. A number of lab tests will be done post-transplant to determine how well the kidney is functioning.

Conditions

• Kidney Transplantation
• Renal Transplantation
• Reperfusion Injury

Interventions

Type	Name	Description
DRUG	Myfortic (mycophenolic acid)	720mg twice a day for 7 days prior to transplantation
DRUG	Myfortic (mycophenolic acid)	720mg twice a day after transplant
DRUG	Thymoglobulin (anti-thymocyte globulin)	up to 25 mg will be infused into the renal artery of a donor kidney prior to transplantation into the recipient.
DRUG	Thymoglobulin (anti-thymocyte globulin)	standard of care for Georgetown University Hospital: 1.5 mg/kg/day infused over 6 hours.

Timeline

• Start date: 2010-06-01
• Primary completion: 2012-06-01
• Completion: 2012-06-01
• First posted: 2010-06-24
• Last updated: 2014-06-09